Medwell Capital is a Canadian biotech company engaged in the development and commercialization of novel therapeutic technologies with emphasis on the treatment of Multiple Sclerosis (MS). en-ca Medwell Capital. All rights reserved. http://www.medwellcapital.com May 7, 2012 - Medwell Capital Corp. (TSX-V: MWC) today advised that Dr. Karen Meerovitch, Senior Director of Drug Discovery at Mimetogen Pharmaceuticals presented the Company's recent Phase II results for MIM-D3 in the treatment of Dry Eye disease in a poster session during the Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO). The poster is entitled "Safety and Efficacy of Topical Ophthalmic MIM-D3, a novel TrkA Receptor Agonist, in a Phase 2 Clinical Trial for the Treatment of Dry Eye." The ARVO conference is one of the most widely attended conferences in the fields of vision and ophthalmology and is being held from May 6-10, 2012 in Fort Lauderdale, Florida. Biotechnology http://www.medwellcapital.com/display-press-release.php?id=240 http://www.medwellcapital.com/display-press-release.php?id=240 MEDWELL CAPITAL GRANTS STOCK OPTIONS Biotechnology http://www.medwellcapital.com/display-press-release.php?id=239 http://www.medwellcapital.com/display-press-release.php?id=239 March 26, 2012 - Medwell Capital Corp. (TSX-V: MWC) today announced the appointment of Tami Reich, CMA, to the position of Chief Financial Officer. Ms. Reich will take over from Brent Johnston as CFO on April 2, 2012. Biotechnology http://www.medwellcapital.com/display-press-release.php?id=238 http://www.medwellcapital.com/display-press-release.php?id=238 March 23, 2012 - Medwell Capital Corp. (TSX-V: MWC) today advised shareholders that the Alberta Securities Commission (ASC) and the British Columbia Securities Commission (BCSC) are warning investors of what appears to be a andlsquo;recovery room' scheme that is reportedly targeting Medwell Capital shareholders. Medwell Capital advises shareholders that it does not have any contact with the individuals involved in this scheme. Biotechnology http://www.medwellcapital.com/display-press-release.php?id=237 http://www.medwellcapital.com/display-press-release.php?id=237 March 21, 2012 -Medwell Capital Corp. (TSX-V: MWC) today announced financial and operational results for the year ended December 31, 2011. Biotechnology http://www.medwellcapital.com/display-press-release.php?id=236 http://www.medwellcapital.com/display-press-release.php?id=236 November 21, 2011 - Medwell Capital Corp. (TSX-V: MWC) today announced that the Company completed its adoption of International Financial Reporting Standards ("IFRS") accounting standards with the filing of amended financial statements for the three months ended March 31, 2011 and the three and six months ended June 30, 2011. The adoption of IFRS had no effect on the financial results previously reported by the Company. Biotechnology http://www.medwellcapital.com/display-press-release.php?id=233 http://www.medwellcapital.com/display-press-release.php?id=233 November 21, 2011 - Medwell Capital Corp. (TSX-V: MWC) today announced financial and operational results for the three and nine months ended September 30, 2011. Biotechnology http://www.medwellcapital.com/display-press-release.php?id=234 http://www.medwellcapital.com/display-press-release.php?id=234 October 18th, 2011 - Medwell Capital Corp. ("Medwell") today announced that it has made a further $880,000 investment in Mimetogen Phamaceuticals Inc. ("Mimetogen"). This investment is the final tranche of the $2 Million funding by Medwell announced on February 25, 2011. Biotechnology http://www.medwellcapital.com/display-press-release.php?id=232 http://www.medwellcapital.com/display-press-release.php?id=232 October 3, 2011 - Medwell Capital Corp. (TSX-V: MWC) today announced that the Company will present its financial statements in accordance with International Financial Reporting Standards ("IFRS"). Biotechnology http://www.medwellcapital.com/display-press-release.php?id=231 http://www.medwellcapital.com/display-press-release.php?id=231 TORONTO, Ontario and EDMONTON, Alberta - September 9, 2011 - Spectral Diagnostics Inc. ("Spectral") (TSX: SDI) and Medwell Capital Corp. ("Medwell") (TSX-V: MWC) today announced that they have completed their previously announced plan of arrangement (the "Arrangement"), pursuant to which Medwell acquired a further 33,333,333 Spectral common shares (the "Spectral Shares") for $10 million, at a subscription price of $0.30 per share, the gross proceeds of which will be used primarily to advance Spectral's Toraymyxin, a treatment for severe sepsis, through to the end of its U.S. Phase III EUPHRATES trial and data release. Pursuant to the Arrangement, Medwell also distributed 54,282,834 Spectral Shares to its shareholders, representing approximately $16.3 million in value based on the $0.30 Spectral Share subscription price. Biotechnology http://www.medwellcapital.com/display-press-release.php?id=230 http://www.medwellcapital.com/display-press-release.php?id=230 August 29, 2011 - Medwell Capital Corp. (TSX-V: MWC) today announced financial and operational results for the three and six months ended June 30, 2011. Biotechnology http://www.medwellcapital.com/display-press-release.php?id=229 http://www.medwellcapital.com/display-press-release.php?id=229 TORONTO, Ontario and EDMONTON, Alberta - August 29, 2011 - Spectral Diagnostics Inc. ("Spectral") (TSX: SDI) and Medwell Capital Corp. ("Medwell") (TSX-V: MWC), today announced that the Court of the Queen's Bench of Alberta today approved their previously announced plan of arrangement (the "Arrangement"). Biotechnology http://www.medwellcapital.com/display-press-release.php?id=228 http://www.medwellcapital.com/display-press-release.php?id=228 August 26, 2011 - Medwell Capital Corp. (TSX-V:MWC) ("Medwell") is pleased to announce that at the Annual General and Special meeting of the shareholders of Medwell held earlier today, shareholders approved all proposed resolutions including the previously announced plan of arrangement (the "Arrangement") with Spectral Diagnostics Inc. (TSX:SDI) ("Spectral"). Biotechnology http://www.medwellcapital.com/display-press-release.php?id=227 http://www.medwellcapital.com/display-press-release.php?id=227 TWO LEADING INDEPENDENT ADVISORY SERVICES RECOMMEND THAT MEDWELL SHAREHOLDERS VOTE FOR ALL PROPOSED RESOLUTIONS Biotechnology http://www.medwellcapital.com/display-press-release.php?id=226 http://www.medwellcapital.com/display-press-release.php?id=226 EDMONTON, Alberta - July 15, 2011 - Medwell Capital Corp. ("Medwell") (TSX-V: MWC), today announced that is has been granted an Interim Order by the Court of Queen's Bench of Alberta in respect of its plan of arrangement with Spectral Diagnostics Inc. ("Spectral"). Pursuant to the Interim Order, Medwell will hold an Annual General and Special Meeting of shareholders on August 26, 2011 where shareholders will consider and vote upon, among other things, the plan of arrangement. Medwell also announces that the plan of arrangement has been amended to provide for the re-pricing of stock options held by persons who are not insiders of Medwell (the "Non-Insider Options"). The 1,995,125 Non-Insider Options with an exercise price of $0.50 per share will have their exercise price reduced to $0.24 per share, the 415,000 Non-Insider Options with an exercise price of $0.37 per share will have their exercise price reduced to $0.178 per share and the 817,500 Non-Insider Options with an exercise price of $0.295 per share will have their exercise price reduced to $0.142 per share. None of the options held by insiders will have their exercise prices reduced as a result of the plan of arrangement. Biotechnology http://www.medwellcapital.com/display-press-release.php?id=225 http://www.medwellcapital.com/display-press-release.php?id=225 $10 Million to be invested by Medwell in additional Spectral shares Biotechnology http://www.medwellcapital.com/display-press-release.php?id=224 http://www.medwellcapital.com/display-press-release.php?id=224 June 27, 2011 - Mimetogen Pharmaceuticals Inc. ("Mimetogen") today announced positive top line data from the Phase II clinical trial of MIM-D3 for dry eye disease. The trial demonstrated statistically significant improvements in signs and symptoms with its low (1%) and high (5%) doses of MIM-D3, together with excellent safety and tolerability profiles. Mimetogen is in the process of completing its analysis of the data, and intends to present further details at a future medical conference. Biotechnology http://www.medwellcapital.com/display-press-release.php?id=223 http://www.medwellcapital.com/display-press-release.php?id=223   Biotechnology http://www.medwellcapital.com/display-press-release.php?id=222 http://www.medwellcapital.com/display-press-release.php?id=222 yle="text-align: center">Medwell Capital Announces that Mimetogen Pharmaceutical Inc. Completes Patient Recruitment in Phase II Clinical Trial for Dry Eye Disease Biotechnology http://www.medwellcapital.com/display-press-release.php?id=221 http://www.medwellcapital.com/display-press-release.php?id=221 yle="text-align: center">Advisory Contract between Medwell Capital and Spectral Diagnostics Increases Biotechnology http://www.medwellcapital.com/display-press-release.php?id=219 http://www.medwellcapital.com/display-press-release.php?id=219 yle="text-align: center">MEDWELL CAPITAL AND A CONSORTIUM OF BUYERS ACQUIRE SPECTRAL DIAGNOSTICS SHARES FROM GROWTHWORKS CANADIAN FUND Biotechnology http://www.medwellcapital.com/display-press-release.php?id=218 http://www.medwellcapital.com/display-press-release.php?id=218 yle="text-align: center">Medwell Capital Announces $2 Million Investment in Mimetogen Pharmaceuticals Biotechnology http://www.medwellcapital.com/display-press-release.php?id=217 http://www.medwellcapital.com/display-press-release.php?id=217 February 11, 2011 - Medwell Capital Corp. (TSX-V: MWC) today announced financial and operational results for the year ended December 31, 2010. Biotechnology http://www.medwellcapital.com/display-press-release.php?id=215 http://www.medwellcapital.com/display-press-release.php?id=215 November 10, 2010 - Medwell Capital Corp. (TSX: MWC), today announced financial and operational results for the three and nine months ended September 30, 2010. Biotechnology http://www.medwellcapital.com/display-press-release.php?id=214 http://www.medwellcapital.com/display-press-release.php?id=214 October 5, 2010 - Medwell Capital Corp. (TSX: MWC) today announced Mr. Kjell Stenberg is no longer with the Company as an officer and director. Biotechnology http://www.medwellcapital.com/display-press-release.php?id=213 http://www.medwellcapital.com/display-press-release.php?id=213 September 9, 2010 - Medwell Capital Corp. (TSX: MWC) today announced that Mr. Kevin Giese, President and CEO, will present at the Rodman and Renshaw Annual Global Investment Conference in New York City. Biotechnology http://www.medwellcapital.com/display-press-release.php?id=212 http://www.medwellcapital.com/display-press-release.php?id=212 September 7, 2010 - Medwell Capital Corp. (TSX: MWC) today announced that, further to recent discussions with the Toronto Stock Exchange (the "TSX"), it will be proceeding with a voluntary delisting of its Class A common shares from the TSX and have applied for a listing of its Class A common shares on the TSX Venture Exchange ("TSXV"). The precise timing of the delisting from the TSX and the planned listing on the TSXV are not yet known and Medwell will make a further announcement when those details are available. Biotechnology http://www.medwellcapital.com/display-press-release.php?id=211 http://www.medwellcapital.com/display-press-release.php?id=211 FOR IMMEDIATE RELEASE Biotechnology http://www.medwellcapital.com/display-press-release.php?id=210 http://www.medwellcapital.com/display-press-release.php?id=210 July 6, 2010 - BioMS Medical Corp. (TSX: MS) today announced it has changed its name to Medwell Capital Corp. ("Medwell" or "the Company"). Shares of Medwell will continue trading on the Toronto Stock Exchange under the symbol andlsquo;MS' until the end of the trading on July 7, 2010. On Thursday, July 8, 2010, Medwell will begin trading under the new symbol andlsquo;MWC'. Biotechnology http://www.medwellcapital.com/display-press-release.php?id=209 http://www.medwellcapital.com/display-press-release.php?id=209 May 14, 2010 - BioMS Medical Corp. (TSX: MS), today announced financial and operational results for the three months ended March 31, 2010. Biotechnology http://www.medwellcapital.com/display-press-release.php?id=208 http://www.medwellcapital.com/display-press-release.php?id=208 May 3, 2010 - BioMS Medical Corp. (TSX: MS), today announced its updated corporate strategy. The Company's new strategy will encompass becoming a full service provider in the healthcare industry, whereby BioMS will directly invest in and advise companies on strategy, financing, mergers and acquisitions (MandA), licensing transactions and undertake technology development. The Company also announced it has hired Mr. Nitin Kaushal, a leading healthcare investment banker, as Executive Vice President and Managing Director. Biotechnology http://www.medwellcapital.com/display-press-release.php?id=207 http://www.medwellcapital.com/display-press-release.php?id=207 April 30, 2010 - BioMS Medical Corp. (TSX: MS), today announced that the University of Alberta, a major shareholder of the Company, has sold 12,915,365 BioMS Medical shares. Biotechnology http://www.medwellcapital.com/display-press-release.php?id=206 http://www.medwellcapital.com/display-press-release.php?id=206 March 16, 2010 - BioMS Medical Corp. (TSX: MS), today announced financial and operational results for the year ended December 31, 2009. Biotechnology http://www.medwellcapital.com/display-press-release.php?id=205 http://www.medwellcapital.com/display-press-release.php?id=205 March 3, 2010 - BioMS Medical Corp. (TSX: MS) today reported that Spectral Diagnostics (TSX: SDI) has received Investigational Device Exemption (IDE) approval from the U.S. Food and Drug Administration (FDA) for Toraymyxinandtrade;. Spectral Diagnostics and BioMS have entered into a services agreement whereby BioMS will assist Spectral, as required, in its commercialization of Toraymyxinandtrade;, a therapeutic hemoperfusion device for the treatment of severe sepsis. This approval permits Spectral to initiate its planned pivotal trial for Toraymyxinandtrade; in the United States. Biotechnology http://www.medwellcapital.com/display-press-release.php?id=203 http://www.medwellcapital.com/display-press-release.php?id=203 March 3, 2010 - BioMS Medical Corp. (TSX: MS) acquired pursuant to a private placement of units, beneficial ownership and control over 30,000,000 common shares and 15,000,000 common shares purchase warrants of Spectral Diagnostics Inc. ("Spectral").  The 30,000,000 common shares represent 39.57% of the issued and outstanding common shares of Spectral and the warrants represent 61.5% of the warrants issued in the private placement.  Assuming BioMS exercises the warrants and acquires an additional 15,000,000 common shares of Spectral, it would hold 45,000,000 common shares representing 49.55% of the partially diluted issued and outstanding common shares of Spectral.  The units were acquired at a price of $0.40 per unit.  Biotechnology http://www.medwellcapital.com/display-press-release.php?id=204 http://www.medwellcapital.com/display-press-release.php?id=204 BioMS Medical makes strategic investment of $12 million in Spectral Biotechnology http://www.medwellcapital.com/display-press-release.php?id=201 http://www.medwellcapital.com/display-press-release.php?id=201 December 17, 2009 - BioMS Medical Corp. (TSX: MS) today provided the following update on corporate developments: Biotechnology http://www.medwellcapital.com/display-press-release.php?id=202 http://www.medwellcapital.com/display-press-release.php?id=202 November 12, 2009 - BioMS Medical Corp. (TSX: MS) today announced financial and operational results for the three and nine months ended September 30, 2009. Biotechnology http://www.medwellcapital.com/display-press-release.php?id=200 http://www.medwellcapital.com/display-press-release.php?id=200 September 2, 2009 - BioMS Medical Corp. (TSX: MS), today provided an update on developments in respect of dirucotide, its drug candidate for multiple sclerosis (MS): Biotechnology http://www.medwellcapital.com/display-press-release.php?id=199 http://www.medwellcapital.com/display-press-release.php?id=199 INDIANAPOLIS, Indiana and EDMONTON, Alberta, July 27, 2009 - Eli Lilly and Company (NYSE: LLY) and BioMS Medical Corp. (TSX: MS) today announced that dirucotide did not meet the primary endpoint of delaying disease progression, as measured by the Expanded Disability Status Scale (EDSS), during the two-year MAESTRO-01 Phase III trial in patients with secondary progressive multiple sclerosis (SPMS). In addition, there were no statistically significant differences between dirucotide and placebo on the secondary endpoints of the study. Biotechnology http://www.medwellcapital.com/display-press-release.php?id=198 http://www.medwellcapital.com/display-press-release.php?id=198 July 17, 2009 - BioMS Medical Corp. (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced financial and operational results for the three and six months ended June 30, 2009. Biotechnology http://www.medwellcapital.com/display-press-release.php?id=197 http://www.medwellcapital.com/display-press-release.php?id=197 May 28, 2009 - BioMS Medical Corp (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced that Mr. Randy Stroud, Vice President Regulatory Affairs, will present at the Canadian Society for Pharmaceutical Sciences 12th Annual Meeting and Symposium. Biotechnology http://www.medwellcapital.com/display-press-release.php?id=196 http://www.medwellcapital.com/display-press-release.php?id=196 "BioMS/Eli Lilly - Dissecting a Billion Dollar Collaboration" Biotechnology http://www.medwellcapital.com/display-press-release.php?id=195 http://www.medwellcapital.com/display-press-release.php?id=195 May 11, 2009 - BioMS Medical Corp. (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced financial and operational results for the first quarter, ended March 31, 2009. Biotechnology http://www.medwellcapital.com/display-press-release.php?id=194 http://www.medwellcapital.com/display-press-release.php?id=194 April 29, 2009 - BioMS Medical Corp (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced that Mr. Kevin Giese, President and CEO, will present at a session entitled "Leveraging on energy wealth: the development of a world class technology sector" as part of the Alberta Economic Forum in Geneva in Switzerland. Biotechnology http://www.medwellcapital.com/display-press-release.php?id=193 http://www.medwellcapital.com/display-press-release.php?id=193 April 24, 2009 - BioMS Medical Corp (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced that Mr. Tony Hesby, Executive Vice President, will present at BioFinance 2009 in Toronto. Biotechnology http://www.medwellcapital.com/display-press-release.php?id=192 http://www.medwellcapital.com/display-press-release.php?id=192 April 21, 2009 - BioMS Medical Corp. (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced that the independent Data Safety Monitoring Board (DSMB) for the Company's pivotal phase III MAESTRO-01 Canadian/European trial of dirucotide in patients with secondary progressive MS has completed a safety analysis and recommended that the trial continue as per the protocol. Biotechnology http://www.medwellcapital.com/display-press-release.php?id=191 http://www.medwellcapital.com/display-press-release.php?id=191 April 14, 2009 - BioMS Medical Corp. (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced that the independent Data Safety Monitoring Board (DSMB) for the Company's U.S. pivotal phase III MAESTRO-03 trial of dirucotide in patients with secondary progressive MS has completed a safety analysis and recommended that the trial continue as per the protocol. Biotechnology http://www.medwellcapital.com/display-press-release.php?id=190 http://www.medwellcapital.com/display-press-release.php?id=190 March 17, 2009 - BioMS Medical Corp. (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced financial and operational results for the year ended December 31, 2008. Biotechnology http://www.medwellcapital.com/display-press-release.php?id=189 http://www.medwellcapital.com/display-press-release.php?id=189 March 2, 2009 - BioMS Medical Corp (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), announced that effective on March 16, 2009 the exercise term of 11,500,000 share purchase warrants, each of which entitles the holder to purchase one Class A common share at a price of $5.00 per share, will be extended from March 23, 2009 to December 31, 2009. Biotechnology http://www.medwellcapital.com/display-press-release.php?id=188 http://www.medwellcapital.com/display-press-release.php?id=188 February 6, 2009 - BioMS Medical Corp (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced that Ms. Amanda Stadel, Director Investor Relations, will present at a session hosted by BioAlberta, Alberta's life science industry association, as part of the 7th Annual BioPartnering North America Conference in Vancouver. Biotechnology http://www.medwellcapital.com/display-press-release.php?id=187 http://www.medwellcapital.com/display-press-release.php?id=187 February 5, 2009 - BioMS Medical Corp (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced that Mr. Kevin Giese, President and CEO, will present at The 11th Annual BIO CEO and Investor Conference in New York. Biotechnology http://www.medwellcapital.com/display-press-release.php?id=186 http://www.medwellcapital.com/display-press-release.php?id=186 January 30, 2009 - BioMS Medical Corp. (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced results from MINDSET-01, an exploratory phase II clinical trial evaluating dirucotide in patients with relapsing-remitting MS. The lead clinical development program for dirucotide is for secondary progressive MS where it is being evaluated in two ongoing phase III trials in the United States, Canada and Europe, with results from the Canadian and European MAESTRO-01 trial expected in the second half of 2009. Biotechnology http://www.medwellcapital.com/display-press-release.php?id=185 http://www.medwellcapital.com/display-press-release.php?id=185 December 11, 2008 - BioMS Medical Corp (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced that the Company was the recipient of the "Licensing Deal of the Year Award" at the 4th Annual Scrip Awards held in London, U.K. In December 2007, BioMS entered into a licensing and development agreement granting Eli Lilly and Company (Lilly) exclusive worldwide rights to dirucotide, for the treatment of MS, in exchange for an US$87 million upfront payment, potential development and sales milestones up to US$410 million and escalating royalties on sales. Biotechnology http://www.medwellcapital.com/display-press-release.php?id=184 http://www.medwellcapital.com/display-press-release.php?id=184 November 6, 2008 - BioMS Medical Corp. (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced financial and operational results for the third quarter ended September 30, 2008. BioMS Medical, in partnership with Eli Lilly and Company (Lilly), is developing dirucotide (MBP8298), a drug for the treatment of MS undergoing pivotal trials in Canada, Europe and the U.S. Biotechnology http://www.medwellcapital.com/display-press-release.php?id=176 http://www.medwellcapital.com/display-press-release.php?id=176 November 5, 2008 - BioMS Medical Corp (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced that Mr. Kevin Giese, President and CEO, will present at the Rodman and Renshaw 10th Annual Healthcare Conference in New York. Biotechnology http://www.medwellcapital.com/display-press-release.php?id=175 http://www.medwellcapital.com/display-press-release.php?id=175 October 6, 2008 - BioMS Medical Corp. (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced that the independent Data Safety Monitoring Board (DSMB) for the Company's phase II MINDSET-01 trial of dirucotide (MBP8298) in patients with relapsing-remitting MS has completed a safety analysis and recommended that the trial continue as per the protocol. Biotechnology http://www.medwellcapital.com/display-press-release.php?id=174 http://www.medwellcapital.com/display-press-release.php?id=174 October 3, 2008 - BioMS Medical Corp. (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced that the independent Data Safety Monitoring Board (DSMB) for the Company's U.S. pivotal phase III MAESTRO-03 trial of dirucotide (MBP8298) in patients with secondary progressive MS has completed a safety analysis and recommended that the trial continue as per the protocol. Biotechnology http://www.medwellcapital.com/display-press-release.php?id=173 http://www.medwellcapital.com/display-press-release.php?id=173 September 30, 2008 - BioMS Medical Corp (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced that Mr. Tony Hesby, Executive Vice President, Corporate Affairs, will present at BioContact 2008 in Québec City. Biotechnology http://www.medwellcapital.com/display-press-release.php?id=172 http://www.medwellcapital.com/display-press-release.php?id=172 US$10 million received based on the positive review of interim analysis for international pivotal multiple sclerosis trial Biotechnology http://www.medwellcapital.com/display-press-release.php?id=171 http://www.medwellcapital.com/display-press-release.php?id=171 September 19, 2008 - BioMS Medical Corp (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced that Mr. Kevin Giese, President and CEO, will present at the UBS Global Life Sciences Conference in New York. Biotechnology http://www.medwellcapital.com/display-press-release.php?id=169 http://www.medwellcapital.com/display-press-release.php?id=169 September 19, 2008 - BioMS Medical Corp (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced that Mr. Tony Hesby, Executive Vice President, Corporate Affairs, will present at the Sachs Associates 8th Annual Biotech in Europe Investor Forum in Zurich, Switzerland. Biotechnology http://www.medwellcapital.com/display-press-release.php?id=170 http://www.medwellcapital.com/display-press-release.php?id=170 September 4, 2008 - BioMS Medical Corp. (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced that the Food and Drug Administration (FDA) of the United States has granted fast track designation for the Company's lead drug, dirucotide (MBP8298), for the treatment of secondary progressive MS (SPMS). Dirucotide (MBP8298) is currently being evaluated in a U.S. pivotal phase III trial, named MAESTRO-03, at 68 sites with approximately 510 patients. Biotechnology http://www.medwellcapital.com/display-press-release.php?id=168 http://www.medwellcapital.com/display-press-release.php?id=168 September 3, 2008 - BioMS Medical Corp (TSX: MS) a leading developer in the treatment of multiple sclerosis (MS), announced today that it is renewing its normal course issuer bid. Under the bid, which will be conducted pursuant to the rules of the Toronto Stock Exchange ("TSX"), the Company may purchase up to 1,000,000 of its Class A common shares (the "Common Shares") representing approximately 1.1% of the Company's issued and outstanding Common Shares. Biotechnology http://www.medwellcapital.com/display-press-release.php?id=167 http://www.medwellcapital.com/display-press-release.php?id=167 Milestone triggers $10 million payment from Eli Lilly and Company Biotechnology http://www.medwellcapital.com/display-press-release.php?id=166 http://www.medwellcapital.com/display-press-release.php?id=166 August 12, 2008 - BioMS Medical Corp. (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced financial and operational results for the second quarter ended June 30, 2008. BioMS Medical, in partnership with Eli Lilly and Company (Lilly), is developing MBP8298 (dirucotide), a drug for the treatment of MS undergoing pivotal trials in Canada, Europe and the US. Biotechnology http://www.medwellcapital.com/display-press-release.php?id=165 http://www.medwellcapital.com/display-press-release.php?id=165 August 1, 2008 - BioMS Medical Corp. (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced that it has completed patient recruitment in its phase III clinical trial of MBP8298 (dirucotide) for the treatment of secondary progressive MS (SPMS). The trial, named MAESTRO-03, includes approximately 510 patients, and is being conducted at 68 trial sites in the U.S. Biotechnology http://www.medwellcapital.com/display-press-release.php?id=164 http://www.medwellcapital.com/display-press-release.php?id=164 July 30, 2008 - BioMS Medical Corp (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced that Mr. Kevin Giese, President and CEO, will present at the BMO Capital Markets "Focus on Healthcare Conference" in New York. Biotechnology http://www.medwellcapital.com/display-press-release.php?id=163 http://www.medwellcapital.com/display-press-release.php?id=163 July 17, 2008 - BioMS Medical Corp. (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced that the independent Data Safety Monitoring Board (DSMB) for the Company's phase II MINDSET-01 trial of MBP8298 (dirucotide) in patients with relapsing-remitting MS has completed a safety analysis and recommended that the trial continue as per the protocol. Biotechnology http://www.medwellcapital.com/display-press-release.php?id=160 http://www.medwellcapital.com/display-press-release.php?id=160 June 18, 2008 - BioMS Medical Corp (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced that Mr. Kevin Giese, President and CEO, will present at the Jefferies 2nd Annual Healthcare Conference in New York. Biotechnology http://www.medwellcapital.com/display-press-release.php?id=158 http://www.medwellcapital.com/display-press-release.php?id=158 June 12, 2008 - BioMS Medical Corp (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced that Mr. Kevin Giese, President and CEO, will present at the Business Forum at the 2008 BIO International Convention in San Diego, California. Biotechnology http://www.medwellcapital.com/display-press-release.php?id=157 http://www.medwellcapital.com/display-press-release.php?id=157 Company to receive Gold Leaf Award from BIOTECanada at BIO 2008 Biotechnology http://www.medwellcapital.com/display-press-release.php?id=156 http://www.medwellcapital.com/display-press-release.php?id=156 May 27, 2008 - BioMS Medical Corp. (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced that the independent Data Safety Monitoring Board (DSMB) for the Company's phase II MINDSET-01 trial of MBP8298 (dirucotide) in patients with relapsing-remitting MS has completed a safety analysis and recommended that the trial continue as per the protocol. Biotechnology http://www.medwellcapital.com/display-press-release.php?id=155 http://www.medwellcapital.com/display-press-release.php?id=155 May 15, 2008 - BioMS Medical Corp. (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced financial and operational results for the first quarter ended March 31, 2008. BioMS, in partnership with Eli Lilly and Company, is developing dirucotide (also known as MBP8298), a synthetic peptide drug for the treatment of MS undergoing pivotal trials in Canada, Europe and the US. Biotechnology http://www.medwellcapital.com/display-press-release.php?id=22 http://www.medwellcapital.com/display-press-release.php?id=22 May 13, 2008 - BioMS Medical Corp (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced that Dr. Mark Krantz, Vice President Scientific Affairs, BioMS Medical, will present at the TIDES - Oligonucleotide and Peptide Technology and Product Development Conference in Las Vegas. Biotechnology http://www.medwellcapital.com/display-press-release.php?id=153 http://www.medwellcapital.com/display-press-release.php?id=153 May 12, 2008 - BioMS Medical Corp (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced that Mr. Kevin Giese, President and CEO, will present at the Rodman and Renshaw 5th Annual Global Healthcare Conference in Monte Carlo, Monaco Biotechnology http://www.medwellcapital.com/display-press-release.php?id=152 http://www.medwellcapital.com/display-press-release.php?id=152 HYC750 out-licensed to Orcrist Biotechnology http://www.medwellcapital.com/display-press-release.php?id=151 http://www.medwellcapital.com/display-press-release.php?id=151 May 5, 2008 - BioMS Medical Corp (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), will hold its Annual General Meeting on Friday, May 9, 2008, at 2:00 p.m. (MT), 4:00 p.m. (ET). Biotechnology http://www.medwellcapital.com/display-press-release.php?id=150 http://www.medwellcapital.com/display-press-release.php?id=150 "Anatomy of a Deal - BioMS Medical and Eli Lilly and Company" Biotechnology http://www.medwellcapital.com/display-press-release.php?id=149 http://www.medwellcapital.com/display-press-release.php?id=149 April 15, 2008 - BioMS Medical Corp. (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced that the independent Data Safety Monitoring Board (DSMB) has reviewed data from the Company's on-going MAESTRO-03 U.S. pivotal phase III clinical trial of MBP8298 for the treatment of secondary progressive MS and recommended that the trial continue. Biotechnology http://www.medwellcapital.com/display-press-release.php?id=147 http://www.medwellcapital.com/display-press-release.php?id=147 April 15, 2008 - BioMS Medical Corp (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced that Mr. Ryan Giese, Vice President Corporate Communication, will present at the EQUITIES Magazine's 57th Anniversary Spring Conference. Biotechnology http://www.medwellcapital.com/display-press-release.php?id=148 http://www.medwellcapital.com/display-press-release.php?id=148 March 24th, 2008 - BioMS Medical Corp (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced that Mr. Kevin Giese, President and CEO, will present at the BioCentury "Future Leaders in the Biotech Industry" Conference in New York. Biotechnology http://www.medwellcapital.com/display-press-release.php?id=180 http://www.medwellcapital.com/display-press-release.php?id=180 March 24th, 2008 - BioMS Medical Corp (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced that Mr. Kevin Giese, President and CEO, will present at the BioCentury "Future Leaders in the Biotech Industry" Conference in New York. Biotechnology http://www.medwellcapital.com/display-press-release.php?id=146 http://www.medwellcapital.com/display-press-release.php?id=146 March 18, 2008 - BioMS Medical Corp. (TSX: MS), a leading developer in the treatment of multiple sclerosis ("MS"), today announced financial and operational results for the year ended December 31, 2007. Biotechnology http://www.medwellcapital.com/display-press-release.php?id=21 http://www.medwellcapital.com/display-press-release.php?id=21 March 3, 2008 - BioMS Medical Corp. (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced that the independent Data Safety Monitoring Board (DSMB) for the Company's phase II MINDSET-01 trial of MBP8298 in patients with relapsing-remitting MS has completed a safety analysis and recommended that the trial continue as per the protocol. Biotechnology http://www.medwellcapital.com/display-press-release.php?id=144 http://www.medwellcapital.com/display-press-release.php?id=144 February 21, 2008 - BioMS Medical Corp (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced that Mr. Kevin Giese, President and CEO, will present at the Sachs Associates 7th Annual North America Forum in Boston. Biotechnology http://www.medwellcapital.com/display-press-release.php?id=143 http://www.medwellcapital.com/display-press-release.php?id=143 February 8, 2008 - BioMS Medical Corp (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced that Mr. Kevin Giese, President and CEO, will present at the BIO CEO and Investor Conference 2008 in New York. Biotechnology http://www.medwellcapital.com/display-press-release.php?id=142 http://www.medwellcapital.com/display-press-release.php?id=142 BioMS receives $87 million upfront payment Biotechnology http://www.medwellcapital.com/display-press-release.php?id=141 http://www.medwellcapital.com/display-press-release.php?id=141 January 23, 2008 - BioMS Medical Corp. (TSX: MS) announced today that the Federal Trade Commission (FTC) has cleared the global licensing and development agreement granting Eli Lilly and Company exclusive worldwide rights to BioMS Medical's lead multiple sclerosis (MS) compound, MBP8298. Completion of the licensing transaction had been contingent upon receipt of this clearance under the Hart-Scott-Rodino Anti-Trust Improvements Act. With this condition now satisfied, the transaction may proceed to completion. Biotechnology http://www.medwellcapital.com/display-press-release.php?id=140 http://www.medwellcapital.com/display-press-release.php?id=140 Lilly to Acquire Exclusive Rights to Novel Late-Stage Molecule for the Treatment of Multiple Sclerosis Biotechnology http://www.medwellcapital.com/display-press-release.php?id=139 http://www.medwellcapital.com/display-press-release.php?id=139 December 14, 2007 - BioMS Medical Corp. (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced that following the meeting of the independent Data Safety Monitoring Board (DSMB), the Company has received a recommendation to continue MAESTRO-01, its pivotal phase II/III clinical trial for MBP8298 for the treatment of secondary progressive multiple sclerosis. Biotechnology http://www.medwellcapital.com/display-press-release.php?id=138 http://www.medwellcapital.com/display-press-release.php?id=138 December 11, 2007 - BioMS Medical Corp. (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced that the independent Data Safety Monitoring Board (DSMB) has reviewed data from the Company's on-going MAESTRO-03 U.S. pivotal phase III clinical trial of MBP8298 for the treatment of secondary progressive MS and recommended that the trial continue. Biotechnology http://www.medwellcapital.com/display-press-release.php?id=137 http://www.medwellcapital.com/display-press-release.php?id=137 November 12, 2007 - BioMS Medical Corp. (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced that more than 133 patients have been enrolled in its MAESTRO-03 U.S. pivotal phase III clinical trial of MBP8298 for the treatment of secondary progressive multiple sclerosis (SPMS). An interim safety and efficacy analysis will be performed on data from the first 133 patients enrolled when they have completed 24 months of the clinical trial. Biotechnology http://www.medwellcapital.com/display-press-release.php?id=135 http://www.medwellcapital.com/display-press-release.php?id=135 November 7, 2007 - BioMS Medical Corp. (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced that the independent Data Safety Monitoring Board (DSMB) for the Company's phase II MINDSET-01 trial of MBP8298 in patients with relapsing-remitting MS has completed a safety analysis and recommended that the trial continue as per the protocol. Biotechnology http://www.medwellcapital.com/display-press-release.php?id=134 http://www.medwellcapital.com/display-press-release.php?id=134 October 31, 2007 - BioMS Medical Corp (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced that Mr. Kevin Giese, President and CEO, will present at the Acumen BioFin Rodman and Renshaw 9th Annual Healthcare Conference in New York. Biotechnology http://www.medwellcapital.com/display-press-release.php?id=133 http://www.medwellcapital.com/display-press-release.php?id=133 October 15, 2007 - BioMS Medical Corp. (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced that interim safety observations from MAESTRO-01, the Company's on-going phase III trial of MBP8298 for the treatment of secondary progressive MS, were reported in a poster presentation at the 23rd Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Prague, Czech Republic. A second poster presentation reported the percentage of patients screened for the trial that had the target HLA-DR2/DR4 immune response genes. Biotechnology http://www.medwellcapital.com/display-press-release.php?id=132 http://www.medwellcapital.com/display-press-release.php?id=132 November 14, 2007 - BioMS Medical Corp (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced financial and operational results for the third quarter, ended September 30, 2007. Biotechnology http://www.medwellcapital.com/display-press-release.php?id=20 http://www.medwellcapital.com/display-press-release.php?id=20 September 28, 2007 - BioMS Medical Corp. (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced that Mr. Tony Hesby, Executive Vice President Corporate Affairs, will give a corporate presentation at BioContact 2007 in Québec City. Biotechnology http://www.medwellcapital.com/display-press-release.php?id=131 http://www.medwellcapital.com/display-press-release.php?id=131 August 20, 2007 - BioMS Medical Corp (TSX: MS) a leading developer in the treatment of multiple sclerosis (MS), announced today that it is renewing its normal course issuer bid. Under the bid, which will be conducted pursuant to the rules of the Toronto Stock Exchange ("TSX"), the Company may purchase up to 1,000,000 of its Class A common shares (the "Common Shares") representing approximately 1.09% of the Company's issued and outstanding Common Shares. Biotechnology http://www.medwellcapital.com/display-press-release.php?id=130 http://www.medwellcapital.com/display-press-release.php?id=130 August 14th, 2007 - BioMS Medical Corp (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced financial and operational results for the second quarter ended June 30, 2007. Biotechnology http://www.medwellcapital.com/display-press-release.php?id=19 http://www.medwellcapital.com/display-press-release.php?id=19 July 24, 2007 - BioMS Medical Corp. (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced that the independent Data Safety Monitoring Board (DSMB) for the Company's phase II MINDSET-01 trial of MBP8298 in patients with relapsing-remitting MS has completed a safety analysis and recommended that the trial continue as per the protocol. Biotechnology http://www.medwellcapital.com/display-press-release.php?id=128 http://www.medwellcapital.com/display-press-release.php?id=128 June 25, 2007 - BioMS Medical Corp (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced that Mr. Kevin Giese, President and CEO, will present at the Jefferies Healthcare Conference in New York. Biotechnology http://www.medwellcapital.com/display-press-release.php?id=127 http://www.medwellcapital.com/display-press-release.php?id=127 June 5, 2007 - BioMS Medical Corp (TSX: MS), a leading developer of products for the treatment of multiple sclerosis (MS), today announced that the first patients have been enrolled in MAESTRO-03, its U.S. pivotal phase III clinical trial of MBP8298, a proprietary synthetic peptide for the treatment of multiple sclerosis. The randomized, double-blind study is enrolling approximately 510 secondary progressive MS patients at approximately 60 sites across the U.S. who will be administered either MBP8298 or placebo intravenously every six months for a period of two years. Biotechnology http://www.medwellcapital.com/display-press-release.php?id=126 http://www.medwellcapital.com/display-press-release.php?id=126 Edmonton, AB, June 04 -- BioMS Medical Corp. (Toronto:MS.TO) announces the following Webcast: Biotechnology http://www.medwellcapital.com/display-press-release.php?id=125 http://www.medwellcapital.com/display-press-release.php?id=125 May 15, 2007 - BioMS Medical Corp (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced results for the first quarter ended March 31, 2007. Biotechnology http://www.medwellcapital.com/display-press-release.php?id=18 http://www.medwellcapital.com/display-press-release.php?id=18 May 3, 2007 - BioMS Medical Corp (TSX: MS), a leading developer of products for the treatment of multiple sclerosis (MS), today announced that it has completed patient recruitment in its phase II clinical trial of MBP8298 for the treatment of relapsing-remitting MS (RRMS). The trial, named MINDSET-01, includes approximately 215 patients, and is being conducted at 24 trial sites in six countries across Europe. Biotechnology http://www.medwellcapital.com/display-press-release.php?id=121 http://www.medwellcapital.com/display-press-release.php?id=121 April 20, 2007 - BioMS Medical Corp (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), is pleased to announce Dr. Clyde E. Markowitz as the lead investigator in the United States for the Company's pivotal phase III clinical trial of its lead drug, MBP8298, for the treatment of secondary progressive multiple sclerosis. Biotechnology http://www.medwellcapital.com/display-press-release.php?id=120 http://www.medwellcapital.com/display-press-release.php?id=120 April 5, 2007 - BioMS Medical Corp. (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced that the independent Data Safety Monitoring Board (DSMB) for the Company's pivotal phase II/III MAESTRO-01 trial of MBP8298 in patients with secondary progressive MS has completed a planned interim safety analysis and recommended that the trial continue as per the protocol. Biotechnology http://www.medwellcapital.com/display-press-release.php?id=118 http://www.medwellcapital.com/display-press-release.php?id=118 February 27, 2007 - BioMS Medical Corp (TSX: MS), a leading developer of products for the treatment of multiple sclerosis (MS), today announced that it has initiated MAESTRO-02, the open-label follow-on portion to its MAESTRO-01 pivotal phase II/III clinical trial of MBP8298 for the treatment of secondary progressive MS. Biotechnology http://www.medwellcapital.com/display-press-release.php?id=117 http://www.medwellcapital.com/display-press-release.php?id=117 February 20, 2007 - BioMS Medical Corp (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced results for the fourth quarter and year ended December 31, 2006. Biotechnology http://www.medwellcapital.com/display-press-release.php?id=17 http://www.medwellcapital.com/display-press-release.php?id=17 February 9, 2007 - BioMS Medical Corp (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced that Mr. Kevin Giese, President and CEO, will present at the BIO CEO and Investor Conference 2007 in New York. Biotechnology http://www.medwellcapital.com/display-press-release.php?id=115 http://www.medwellcapital.com/display-press-release.php?id=115 On track to announce interim data in mid-2008 Biotechnology http://www.medwellcapital.com/display-press-release.php?id=114 http://www.medwellcapital.com/display-press-release.php?id=114 January 19, 2007 - BioMS Medical Corp (TSX: MS), a leading developer of products for the treatment of multiple sclerosis (MS), announced today that it has received clearance from the United States Food and Drug Administration (FDA) of its Investigational New Drug Application (IND) for the initiation of a pivotal phase III clinical trial to investigate the use of MBP8298 as a treatment for patients with secondary progressive MS. Biotechnology http://www.medwellcapital.com/display-press-release.php?id=113 http://www.medwellcapital.com/display-press-release.php?id=113 December 7, 2006 - BioMS Medical Corp. (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced that following the sixth meeting of the independent Data Safety Monitoring Board (DSMB), the Company has received a recommendation to continue its pivotal phase II/III clinical trial for MBP8298 for the treatment of secondary progressive multiple sclerosis. Biotechnology http://www.medwellcapital.com/display-press-release.php?id=112 http://www.medwellcapital.com/display-press-release.php?id=112 $27.1 million raised in two-tranche private placement to support advancement of multiple sclerosis drug Biotechnology http://www.medwellcapital.com/display-press-release.php?id=111 http://www.medwellcapital.com/display-press-release.php?id=111 November 24, 2006 - BioMS Medical Corp ("BioMS" or the "Corporation") (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced that it has completed a private placement of 6,128,957 million units at a price of CDN $3.41 per unit, for gross proceeds of CDN $20.9 million. It is anticipated that a further closing of approximately 880,000 units for gross proceeds of approximately $3,000,000 may occur within the next two weeks. Biotechnology http://www.medwellcapital.com/display-press-release.php?id=110 http://www.medwellcapital.com/display-press-release.php?id=110 November 23, 2006 - BioMS Medical Corp (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced that the first patients have been enrolled in its placebo controlled multi-center Phase II clinical trial of MBP8298 for the treatment of relapsing remitting multiple sclerosis (RRMS). Biotechnology http://www.medwellcapital.com/display-press-release.php?id=109 http://www.medwellcapital.com/display-press-release.php?id=109 November 16, 2006 - BioMS Medical Corp (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), is pleased to announce Professor Hans-Peter Hartung as National Coordinator in Germany for the ongoing pivotal phase II/III trial of its lead drug, MBP8298, a proprietary synthetic peptide for the treatment of multiple sclerosis. Professor Hartung is also a member of the Clinical Advisory Group for the international phase II/III trial. Biotechnology http://www.medwellcapital.com/display-press-release.php?id=108 http://www.medwellcapital.com/display-press-release.php?id=108 November 13, 2006 - BioMS Medical Corp (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced results for the third quarter ended September 30, 2006. Biotechnology http://www.medwellcapital.com/display-press-release.php?id=16 http://www.medwellcapital.com/display-press-release.php?id=16 November 3, 2006 - BioMS Medical Corp (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced that Mr. Kevin Giese, President and CEO, will present at the MS Society of Canada, Alberta Division's Annual General Meeting in Calgary, Alberta. Biotechnology http://www.medwellcapital.com/display-press-release.php?id=106 http://www.medwellcapital.com/display-press-release.php?id=106 November 2, 2006 - BioMS Medical Corp (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced that the University of Alberta has received additional patents for the Company's synthetic peptide therapeutic, MBP8298, for the treatment of multiple sclerosis (MS). BioMS Medical licenses these patents on an exclusive worldwide basis from the University of Alberta. Biotechnology http://www.medwellcapital.com/display-press-release.php?id=182 http://www.medwellcapital.com/display-press-release.php?id=182 October 24, 2006 - BioMS Medical Corp (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced it has received approval in all of the Baltic States (Lithuania, Estonia, and Latvia) from their respective agencies to begin enrolling patients into its ongoing pivotal phase II/III trial of MBP8298, a proprietary synthetic peptide for the treatment of secondary progressive multiple sclerosis (SPMS). Biotechnology http://www.medwellcapital.com/display-press-release.php?id=105 http://www.medwellcapital.com/display-press-release.php?id=105 October 12, 2006 - BioMS Medical Corp (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced it has received approval from the National Agency for Medicines to begin enrolling patients in Finland into its ongoing pivotal phase II/III trial of MBP8298, a proprietary synthetic peptide for the treatment of secondary progressive multiple sclerosis (SPMS). Biotechnology http://www.medwellcapital.com/display-press-release.php?id=104 http://www.medwellcapital.com/display-press-release.php?id=104 October 3, 2006 - BioMS Medical Corp (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced that the Company will be presenting at two upcoming forums. Biotechnology http://www.medwellcapital.com/display-press-release.php?id=103 http://www.medwellcapital.com/display-press-release.php?id=103 September 22, 2006 - BioMS Medical Corp (TSX: MS), a leading developer of products for the treatment of multiple sclerosis (MS), is pleased to announce the appointment of Mr. William D. Grace to the Company's Board of Directors. Mr. Grace will serve as Chair of the Company's Audit Committee. Biotechnology http://www.medwellcapital.com/display-press-release.php?id=177 http://www.medwellcapital.com/display-press-release.php?id=177 August 16, 2006 - BioMS Medical Corp. (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced that following the fifth meeting of the independent Data Safety Monitoring Board (DSMB), the Company has received a recommendation to continue its pivotal phase II/III clinical trial for MBP8298 for the treatment of secondary progressive multiple sclerosis. Biotechnology http://www.medwellcapital.com/display-press-release.php?id=102 http://www.medwellcapital.com/display-press-release.php?id=102 More than 300 patients enrolled in pivotal phase II/III multiple sclerosis trial Biotechnology http://www.medwellcapital.com/display-press-release.php?id=15 http://www.medwellcapital.com/display-press-release.php?id=15 August 11, 2006 - BioMS Medical Corp (TSX: MS) a leading developer in the treatment of multiple sclerosis (MS), announced today that it is renewing its normal course issuer bid. Under the bid, which will be conducted pursuant to the rules of the Toronto Stock Exchange ("TSX"), the Company may purchase up to 1,000,000 of its Class A common shares (the "Common Shares") representing approximately 1.5% of the Company's issued and outstanding Common Shares. Biotechnology http://www.medwellcapital.com/display-press-release.php?id=100 http://www.medwellcapital.com/display-press-release.php?id=100 June 22, 2006 - BioMS Medical Corp (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced it has received approval to start patient enrolment in The Netherlands for its pivotal phase II/III clinical trial of MBP8298, a proprietary synthetic peptide for the treatment of secondary progressive multiple sclerosis (SPMS). Approval was received from the Competent Authority in The Netherlands, CCMO (Central Committee on Research Involving Human Subjects). Biotechnology http://www.medwellcapital.com/display-press-release.php?id=99 http://www.medwellcapital.com/display-press-release.php?id=99 Long-term efficacy and safety shown in multiple sclerosis patients Biotechnology http://www.medwellcapital.com/display-press-release.php?id=98 http://www.medwellcapital.com/display-press-release.php?id=98 June 2, 2006 - BioMS Medical Corp (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced that Mark Krantz, PhD, Vice President Scientific Affairs, BioMS Medical, will present at FOCIS 2006 in San Francisco, California. Biotechnology http://www.medwellcapital.com/display-press-release.php?id=97 http://www.medwellcapital.com/display-press-release.php?id=97 June 1, 2006 - BioMS Medical Corp (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced it has successfully completed the private placement of 4,406,800 million units at a price of $3.41 per unit for gross proceeds of $15,027,188. Biotechnology http://www.medwellcapital.com/display-press-release.php?id=96 http://www.medwellcapital.com/display-press-release.php?id=96 May 26, 2006 - BioMS Medical Corp (TSX: MS) today announced that it has entered into definitive agreements with select institutional accredited investors to sell approximately 4.4 million units in a private placement at a price of $3.41 per unit, for gross proceeds of approximately $15 million. Each unit consists of one Class A common share of the Company and one-half of one common share purchase with each whole warrant entitling the holder to purchase one Class A common share at an exercise price of $4.00 per share for a period of four years from the date of closing of the private placement. The private placement is expected to close in the next several days and is subject to approval of the Toronto Stock Exchange and other customary closing conditions. Biotechnology http://www.medwellcapital.com/display-press-release.php?id=181 http://www.medwellcapital.com/display-press-release.php?id=181 May 15, 2006 - BioMS Medical Corp (TSX: MS), a leading developer of a treatment for multiple sclerosis (MS), today announced results for the first quarter ended March 31, 2006. Biotechnology http://www.medwellcapital.com/display-press-release.php?id=14 http://www.medwellcapital.com/display-press-release.php?id=14 May 16, 2006 - BioMS Medical Corp (TSX: MS), a leading developer of products for the treatment of multiple sclerosis (MS), announced that it has received regulatory approval to initiate a phase II human clinical trial to investigate the efficacy and safety of MBP8298 in patients with relapsing-remitting multiple sclerosis (RRMS) in the first of several European countries. Patient enrollment is targeted to commence in the third quarter of this year and BioMS anticipates up to 30 sites will participate. Biotechnology http://www.medwellcapital.com/display-press-release.php?id=95 http://www.medwellcapital.com/display-press-release.php?id=95 May 12, 2006 - BioMS Medical Corp (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced that Mr. Kevin Giese, President and CEO, will present at the Rodman and Renshaw 3rd Annual Global Healthcare Conference. Biotechnology http://www.medwellcapital.com/display-press-release.php?id=93 http://www.medwellcapital.com/display-press-release.php?id=93 May 10, 2006 - BioMS Medical Corp (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced it has received approval from the Danish Medicines Agency to start patient enrolment in Denmark for its pivotal phase II/III clinical trial of MBP8298, a proprietary synthetic peptide for the treatment of secondary progressive multiple sclerosis (SPMS). Biotechnology http://www.medwellcapital.com/display-press-release.php?id=92 http://www.medwellcapital.com/display-press-release.php?id=92 More than 200 patients enrolled in Phase II/III trial for MBP8298 Biotechnology http://www.medwellcapital.com/display-press-release.php?id=91 http://www.medwellcapital.com/display-press-release.php?id=91 May 3, 2006 - BioMS Medical Corp. (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced that following the fourth meeting of the independent Data Safety Monitoring Board (DSMB), the Company has received a recommendation to continue its pivotal phase II/III clinical trial for MBP8298 for the treatment of secondary progressive multiple sclerosis. Biotechnology http://www.medwellcapital.com/display-press-release.php?id=90 http://www.medwellcapital.com/display-press-release.php?id=90 April 28, 2006 - BioMS Medical Corp (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced that Mr. Tony Hesby, Executive Vice President, Corporate Affairs of BioMS Medical, will present at BioFinance 2006 in Toronto. Biotechnology http://www.medwellcapital.com/display-press-release.php?id=89 http://www.medwellcapital.com/display-press-release.php?id=89 April 26, 2006 - BioMS Medical Corp (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced that Dr. Mark Krantz, Vice President Scientific Affairs, BioMS Medical, along with Dr. Marie-Hélène Brichard, Head of Process Development of Lonza Braine S.A., Belgium will present at the TIDES® Conference 2006 in Carlsbad, California. Biotechnology http://www.medwellcapital.com/display-press-release.php?id=88 http://www.medwellcapital.com/display-press-release.php?id=88 March 28, 2006 - BioMS Medical Corp (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced that effective March 24, 2006, its Board of Directors had appointed PricewaterhouseCoopers LLP, Chartered Accountants ("Pricewaterhouse") as the Company's new independent auditors, replacing the firm of Collins Barrow, Chartered Accountants ("Collins Barrow"). Biotechnology http://www.medwellcapital.com/display-press-release.php?id=87 http://www.medwellcapital.com/display-press-release.php?id=87 MBP8298 to be tested in a second major MS patient population Biotechnology http://www.medwellcapital.com/display-press-release.php?id=86 http://www.medwellcapital.com/display-press-release.php?id=86 March 10, 2006 - BioMS Medical Corp. (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced that Mr. Tony Hesby, Executive Vice President Corporate Affairs, will give a corporate presentation at The Sachs Associates 5th Annual North America Forum in Boston. Biotechnology http://www.medwellcapital.com/display-press-release.php?id=85 http://www.medwellcapital.com/display-press-release.php?id=85 March 7, 2006 - BioMS Medical Corp (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced that its proprietary drug candidate MBP8298 delayed disease progression for five years in progressive MS patients with HLA-DR2 or HLA-DR4 immune response genes. Treatment and follow-up of patients from a phase II clinical study demonstrated that patients in this DR2 and DR4 responder group, who comprise up to 75% of MS patients, had a median time to disease progression (worsening) of 78 months compared to 18 months for patients who received placebo. Biotechnology http://www.medwellcapital.com/display-press-release.php?id=179 http://www.medwellcapital.com/display-press-release.php?id=179 February 17, 2006 - BioMS Medical Corp (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced fourth quarter and year-end results for the year ended December 31, 2005. Biotechnology http://www.medwellcapital.com/display-press-release.php?id=13 http://www.medwellcapital.com/display-press-release.php?id=13 February 15, 2006 - BioMS Medical Corp (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), announced that it has secured long-term manufacturing agreements with two global companies, UCB-Bioproducts and Hospira Worldwide Inc., for its lead MS drug MBP8298. Biotechnology http://www.medwellcapital.com/display-press-release.php?id=178 http://www.medwellcapital.com/display-press-release.php?id=178 February 9, 2006 - BioMS Medical Corp. (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced that Mr. Kevin Giese, President and CEO, will present at the BIO CEO and Investor Conference 2006 in New York. Biotechnology http://www.medwellcapital.com/display-press-release.php?id=82 http://www.medwellcapital.com/display-press-release.php?id=82 February 7, 2005 - BioMS Medical Corp. (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced that following the third meeting of the independent Data Safety Monitoring Board (DSMB), the Company has received a recommendation to continue its pivotal phase II/III clinical trial for MBP8298 for the treatment of secondary progressive multiple sclerosis. Biotechnology http://www.medwellcapital.com/display-press-release.php?id=81 http://www.medwellcapital.com/display-press-release.php?id=81 January 26, 2006 - BioMS Medical Corp (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced that it has signed a letter of intent establishing ICON (ICON; NASDAQ: ICLR) as the global clinical research organization (CRO) for the company's ongoing pivotal phase II/III clinical trial for MBP8298 for the treatment of multiple sclerosis. Biotechnology http://www.medwellcapital.com/display-press-release.php?id=80 http://www.medwellcapital.com/display-press-release.php?id=80 January 25, 2006 - BioMS Medical Corp. (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced that Mr. Tony Hesby, Executive Vice President, Corporate Affairs, will give a corporate presentation at The Brean Murray, Carret Small Cap Institutional Investor Conference 2006 in New York. Biotechnology http://www.medwellcapital.com/display-press-release.php?id=79 http://www.medwellcapital.com/display-press-release.php?id=79 January 19, 2006 - BioMS Medical Corp (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced that its President and CEO, Mr. Kevin Giese , has been selected to receive the 2005 BioAlberta Award for Entrepreneurship. Biotechnology http://www.medwellcapital.com/display-press-release.php?id=78 http://www.medwellcapital.com/display-press-release.php?id=78 January 6, 2006 - BioMS Medical Corp (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced that it has exercised its option to purchase additional equity in BioCyDex Inc., a private company based in Edmonton, bringing BioMS Medical's total equity position to 49%. Biotechnology http://www.medwellcapital.com/display-press-release.php?id=77 http://www.medwellcapital.com/display-press-release.php?id=77 December 16, 2005 - BioMS Medical Corp (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), announces that its Board of Directors has adopted a shareholder rights plan designed to encourage the fair treatment of shareholders in connection with any take-over offer for the Corporation. The plan was not adopted in response to an anticipated takeover bid, but as a general planning measure. Biotechnology http://www.medwellcapital.com/display-press-release.php?id=183 http://www.medwellcapital.com/display-press-release.php?id=183 December 6, 2005 - BioMS Medical Corp (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced that the University of Alberta has received thirty-eight additional patents for the Company's synthetic peptide therapeutic, MBP8298, for the treatment of multiple sclerosis (MS). BioMS Medical, through a subsidiary, licenses these patents on an exclusive worldwide basis from the University of Alberta. Biotechnology http://www.medwellcapital.com/display-press-release.php?id=76 http://www.medwellcapital.com/display-press-release.php?id=76 Edmonton, AB - November 28, 2005 /CCN Matthews/ -- BioMS Medical Corp. (TSX: MS) will present at the following forum: Biotechnology http://www.medwellcapital.com/display-press-release.php?id=75 http://www.medwellcapital.com/display-press-release.php?id=75 November 17, 2005 - BioMS Medical Corp (TSX: MS), a leading developer of products for the treatment of multiple sclerosis (MS), is pleased to announce the appointment of Mr. Bryan McKnight to the Company's Board of Directors and Chair of the Audit Committee and Mr. Gordon Politeski as an advisor to the Board pending his nomination as a Director at the Company's next annual meeting of shareholders. Biotechnology http://www.medwellcapital.com/display-press-release.php?id=74 http://www.medwellcapital.com/display-press-release.php?id=74 CONTENT GOES HERE Biotechnology http://www.medwellcapital.com/display-press-release.php?id=12 http://www.medwellcapital.com/display-press-release.php?id=12 November 3, 2005 - BioMS Medical Corp. (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced that Mr. Kevin Giese, President and CEO, will present a corporate update at the Rodman and Renshaw Techvest 7th Annual Healthcare Conference in New York. Biotechnology http://www.medwellcapital.com/display-press-release.php?id=73 http://www.medwellcapital.com/display-press-release.php?id=73 Second Recommendation from Data Safety Monitoring Board Biotechnology http://www.medwellcapital.com/display-press-release.php?id=72 http://www.medwellcapital.com/display-press-release.php?id=72 October 3, 2005 - BioMS Medical Corp. (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced that Mr. Ryan Giese, Vice President Corporate Communications, will present at BioContact Québec 2005. Biotechnology http://www.medwellcapital.com/display-press-release.php?id=71 http://www.medwellcapital.com/display-press-release.php?id=71 September 29, 2005 - BioMS Medical Corp. (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced that Dr. Kjell Stenberg, Chief Operating Officer, will present at the Sachs-Bloomberg 5th Annual Biotech in Europe Investor Forum in Zurich, Switzerland. Biotechnology http://www.medwellcapital.com/display-press-release.php?id=70 http://www.medwellcapital.com/display-press-release.php?id=70 September 12, 2005 - BioMS Medical Corp (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), is pleased to announce Dr. Tomas Olsson as the lead investigator in Sweden for the Company's multi-national pivotal Phase II/III clinical trial of its lead drug, MBP8298, for the treatment of secondary progressive multiple sclerosis. Biotechnology http://www.medwellcapital.com/display-press-release.php?id=69 http://www.medwellcapital.com/display-press-release.php?id=69 Edmonton, AB - August 24, 2005 /CCN Matthews/ -- BioMS Medical Corp. (TSX: MS) will present at the following forum: Biotechnology http://www.medwellcapital.com/display-press-release.php?id=68 http://www.medwellcapital.com/display-press-release.php?id=68 August 23, 2005 - BioMS Medical Corp (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced it has received approval from the Swedish Medical Products Agency (MPA) for its pivotal Phase II/III clinical trial of MBP8298, a proprietary synthetic peptide for the treatment of secondary progressive multiple sclerosis (SPMS). Biotechnology http://www.medwellcapital.com/display-press-release.php?id=67 http://www.medwellcapital.com/display-press-release.php?id=67 August 18, 2005 - BioMS Medical Corp (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced that the independent Data Safety Monitoring Board (DSMB) has reviewed data from the Company's pivotal phase II/III clinical trial of MBP8298 for the treatment of secondary progressive multiple sclerosis and recommended that the trial may continue. Biotechnology http://www.medwellcapital.com/display-press-release.php?id=66 http://www.medwellcapital.com/display-press-release.php?id=66 Aug 12, 2005 - BioMS Medical Corp (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced results for the second quarter ended June 30, 2005. Biotechnology http://www.medwellcapital.com/display-press-release.php?id=11 http://www.medwellcapital.com/display-press-release.php?id=11 Company Expands Pivotal Phase II/III MS Trial Into Europe Biotechnology http://www.medwellcapital.com/display-press-release.php?id=64 http://www.medwellcapital.com/display-press-release.php?id=64 June 16, 2005 - BioMS Medical Corp. (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced that Mr. Kevin Giese, president and CEO of the company, will present at the BIO 2005 business forum in Philadelphia, Pennsylvania. Biotechnology http://www.medwellcapital.com/display-press-release.php?id=63 http://www.medwellcapital.com/display-press-release.php?id=63 May 31, 2005 - BioMS Medical Corp ( TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), is pleased to announce Dr. Carolyn Young, Consultant Neurologist at the Walton Centre for Neurology and Neurosurgery, Liverpool, and honorary senior lecturer at the University of Liverpool, as the United Kingdom lead investigator for the Company's pivotal Phase II/III clinical trial of its lead drug MBP8298 for the treatment of secondary progressive multiple sclerosis. Biotechnology http://www.medwellcapital.com/display-press-release.php?id=62 http://www.medwellcapital.com/display-press-release.php?id=62 May 20, 2005 - BioMS Medical Corp (TSX: MS) a leading developer in the treatment of multiple sclerosis, announced today that it is increasing the number of Class A common shares which may be purchased under its normal course issuer bid from 200,000 shares to 1,000,000 shares, which represents approximately 1.9% of the 51,859,466 issued and outstanding Class A common shares as of August 12, 2004 and approximately 1.6% of the 63,366,766 issued and outstanding Class A common shares as of the date hereof. Biotechnology http://www.medwellcapital.com/display-press-release.php?id=61 http://www.medwellcapital.com/display-press-release.php?id=61 May 17, 2005 - BioMS Medical Corp (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced that the University of Alberta ("U of A"), the controlling shareholder of the Company, has sold 500,000 BioMS Medical shares. Biotechnology http://www.medwellcapital.com/display-press-release.php?id=60 http://www.medwellcapital.com/display-press-release.php?id=60 May 13, 2005 - BioMS Medical Corp (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced results for the first quarter ended March 31, 2005. Biotechnology http://www.medwellcapital.com/display-press-release.php?id=10 http://www.medwellcapital.com/display-press-release.php?id=10 Company selects 30 trial sites across Canada and Europe Biotechnology http://www.medwellcapital.com/display-press-release.php?id=58 http://www.medwellcapital.com/display-press-release.php?id=58 Over-allotment option fully exercised Biotechnology http://www.medwellcapital.com/display-press-release.php?id=57 http://www.medwellcapital.com/display-press-release.php?id=57 Feb 18, 2005 - BioMS Medical Corp (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced fourth quarter and year-end results for the year ended December 31, 2004. Biotechnology http://www.medwellcapital.com/display-press-release.php?id=9 http://www.medwellcapital.com/display-press-release.php?id=9 February 14, 2005 - BioMS Medical Corp (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced it has reached agreement with Fraser Mackenzie Limited ("Fraser Mackenzie") under which Fraser Mackenzie will lead a banking syndicate for a short-form prospectus offering, on a best efforts basis, of 10,000,000 units of the Company at a planned price of $3.60 per unit, which is an average closing price of the last 5 trading days at a 10% discount. An over allotment option of 15% or 1,500,000 units at the issue price will also be granted to accommodate any oversubscriptions above the $36 million offering. Biotechnology http://www.medwellcapital.com/display-press-release.php?id=55 http://www.medwellcapital.com/display-press-release.php?id=55 December 10, 2004 - BioMS Medical Corp (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced it has received a Notice of Acceptance from the UK Medicines and Healthcare products Regulatory Agency (MHRA) for its pivotal Phase II/III clinical trial of MBP8298, a proprietary synthetic peptide for the treatment of secondary progressive multiple sclerosis (SPMS). Biotechnology http://www.medwellcapital.com/display-press-release.php?id=54 http://www.medwellcapital.com/display-press-release.php?id=54 December 9, 2004 - BioMS Medical Corp (TSX: MS) announces that effective on Thursday, December 23, 2004, the term of share purchase warrants (the "Warrants") issued by BioMS, entitling the holders thereof to purchase up to 1,422,247 Class A common shares at a price of $4.30 per share on or before March 17, 2005, has been extended from March 17, 2005 to October 22, 2005 and the exercise price has been reduced from $4.30 per share to $4.00 per share. None of the Warrants are held by insiders of BioMS. Biotechnology http://www.medwellcapital.com/display-press-release.php?id=53 http://www.medwellcapital.com/display-press-release.php?id=53 December 8, 2004 - BioMS Medical Corp (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced that the first patients have been enrolled in its pivotal Phase II/III clinical trial of MBP8298, a proprietary synthetic peptide for the treatment of secondary progressive multiple sclerosis which affects approximately 40% of the estimated 2.5 million MS patients worldwide. Biotechnology http://www.medwellcapital.com/display-press-release.php?id=52 http://www.medwellcapital.com/display-press-release.php?id=52 November 12, 2004 - BioMS Medical Corp (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced financial and operational results for the third quarter, ended September 30, 2004. Biotechnology http://www.medwellcapital.com/display-press-release.php?id=8 http://www.medwellcapital.com/display-press-release.php?id=8 Dr. Mark Freedman announced as Lead Investigator Biotechnology http://www.medwellcapital.com/display-press-release.php?id=50 http://www.medwellcapital.com/display-press-release.php?id=50 Dr. Tony Verco appointed Vice President of Clinical and Medical Affairs Biotechnology http://www.medwellcapital.com/display-press-release.php?id=49 http://www.medwellcapital.com/display-press-release.php?id=49 October 13, 2004 - BioMS Medical Corp (TSX: MS) announces that effective on Thursday, October 21, 2004, the term of share purchase warrants (the "Warrants") issued by BioMS, entitling the holders thereof to purchase up to 1,815,000 Class A common shares at a price of $4.00 per share on or before October 22, 2004, has been extended from October 22, 2004 to October 22, 2005. Biotechnology http://www.medwellcapital.com/display-press-release.php?id=48 http://www.medwellcapital.com/display-press-release.php?id=48 CONTENT GOES HERE Biotechnology http://www.medwellcapital.com/display-press-release.php?id=7 http://www.medwellcapital.com/display-press-release.php?id=7 August 12, 2004 - BioMS Medical Corp (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), announced today that, it is renewing its normal course issuer bid. Under the bid, which will be conducted pursuant to the rules of the Toronto Stock Exchange ("TSX"), the Company may purchase up to 200,000 of its Class A common shares (the "Common Shares") representing approximately 0.4% of the Company's issued and outstanding Common Shares. Biotechnology http://www.medwellcapital.com/display-press-release.php?id=47 http://www.medwellcapital.com/display-press-release.php?id=47 Dr. Leopold Arfors appointed Medical Director of BioMS Biotechnology http://www.medwellcapital.com/display-press-release.php?id=46 http://www.medwellcapital.com/display-press-release.php?id=46 June 7, 2004 - BioMS Medical Corp (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), announced that it has received Health Canada clearance to initiate a pivotal Phase II/III human clinical trial to investigate the use of MBP8298 as a treatment for patients with secondary progressive multiple sclerosis (SPMS). Biotechnology http://www.medwellcapital.com/display-press-release.php?id=45 http://www.medwellcapital.com/display-press-release.php?id=45 May 18, 2004 - BioMS Medical Corp (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), is pleased to announce that it has filed its Clinical Trial Application to the Therapeutic Products Directorate of Health Canada for its proposed pivotal clinical trial in respect of its lead product, MBP8298 for the treatment of secondary progressive multiple sclerosis. Biotechnology http://www.medwellcapital.com/display-press-release.php?id=44 http://www.medwellcapital.com/display-press-release.php?id=44 May 14, 2004 - BioMS Medical Corp (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced financial results for the first quarter ended March 31, 2004. Biotechnology http://www.medwellcapital.com/display-press-release.php?id=6 http://www.medwellcapital.com/display-press-release.php?id=6 May 6, 2004 - BioMS Medical Corp (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced fourth quarter and year-end results for the year ended December 31, 2003. Biotechnology http://www.medwellcapital.com/display-press-release.php?id=5 http://www.medwellcapital.com/display-press-release.php?id=5 March 23, 2004 - BioMS Medical Corp (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced that the University of Alberta has received seventeen additional patents for the Company's synthetic peptide therapeutic, MBP8298, for the treatment of multiple sclerosis (MS). BioMS Medical, through a subsidiary, licenses these patents on an exclusive worldwide basis from the University of Alberta. Biotechnology http://www.medwellcapital.com/display-press-release.php?id=41 http://www.medwellcapital.com/display-press-release.php?id=41 March 18, 2004 - BioMS Medical Corp (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced that it has completed the sale of 2,821,526 units of the Company at a price of $3.30 per Unit for gross proceeds of $9,311,000. Each Unit consists of one Class A common share of the Company and one-half of one non-transferable share purchase warrant. Each whole share purchase warrant entitles the holder to purchase one common share at a price of $4.30 per share on or before March 17, 2005 . Union Securities Ltd. acted as agent. Biotechnology http://www.medwellcapital.com/display-press-release.php?id=40 http://www.medwellcapital.com/display-press-release.php?id=40 December 23, 2003 - BioMS Medical Corp. (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced that it has filed a Preliminary Short Form Prospectus with the securities regulatory authorities in the Provinces of Alberta, British Columbia, Ontario and Quebec, with respect to an offering of units of the Company, each unit consisting of one Class A common share and one-half of one non-transferable share purchase warrant. Each whole share purchase warrant will entitle the holder to purchase a further common share for a period of one year. It is anticipated that the maximum amount to be raised under the offering will be $16,250,000, although the actual maximum amount and the price per unit will be set in light of market conditions. The exercise price of the warrants will be at a $1.00 premium from the offering price of the units. Union Securities Ltd. has agreed to act as agent on a best efforts basis in respect of the offering. Biotechnology http://www.medwellcapital.com/display-press-release.php?id=39 http://www.medwellcapital.com/display-press-release.php?id=39 December 12, 2003 - BioMS Medical Corp (TSX: MS) today announced it intends to file its CTA (Clinical Trial Application) in Canada for approval to commence a Phase III clinical trial in respect of its lead product, MBP8298 for the treatment of secondary progressive multiple sclerosis. Biotechnology http://www.medwellcapital.com/display-press-release.php?id=38 http://www.medwellcapital.com/display-press-release.php?id=38 November 28, 2003 - BioMS Medical Corp (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced financial results for the third quarter ended September 30, 2003. Biotechnology http://www.medwellcapital.com/display-press-release.php?id=4 http://www.medwellcapital.com/display-press-release.php?id=4 MBP8298 pre-CTA package submitted to Health Canada Biotechnology http://www.medwellcapital.com/display-press-release.php?id=36 http://www.medwellcapital.com/display-press-release.php?id=36 October 28, 2003 - BioMS Medical Corp (TSX:MS) today announced it has received proceeds of $825,000 from the exercise of approximately 330,000 broker warrants. Biotechnology http://www.medwellcapital.com/display-press-release.php?id=35 http://www.medwellcapital.com/display-press-release.php?id=35 September 23, 2003 - BioMS Medical Corp (TSX: MS) announces that effective on Tuesday, September 30, 2003, the term of share purchase warrants (the "Warrants") issued or issuable by BioMS, entitling the holders thereof to purchase up to 1,815,000 Class A common shares at a price of $5.80 per share on or before October 22, 2003, has been extended from October 22, 2003 to October 22, 2004 and the exercise price has been reduced from $5.80 per share to $4.00 per share. Biotechnology http://www.medwellcapital.com/display-press-release.php?id=34 http://www.medwellcapital.com/display-press-release.php?id=34 Aug 29, 2003 - BioMS Medical Corp (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced financial results for the second quarter ended June 30, 2003. Biotechnology http://www.medwellcapital.com/display-press-release.php?id=3 http://www.medwellcapital.com/display-press-release.php?id=3 August 7, 2003 - BioMS Medical Corp (TSX: MS) announced today that, subject to regulatory approval, its Board of Directors has authorized the purchase of up to 500,000 of its Class A common shares (the "Common Shares") representing approximately 1% of the Company's Class A Common Shares, under a normal course issuer bid pursuant to the rules of the Toronto Stock Exchange ("TSX"). Biotechnology http://www.medwellcapital.com/display-press-release.php?id=32 http://www.medwellcapital.com/display-press-release.php?id=32 July 31, 2003 - BioMS Medical a leading developer in the treatment of multiple sclerosis, is pleased to announce the appointments of Mark Krantz, PhD, to the newly-created position of Director of Scientific Affairs and Les Ferenczi to the newly-created position of Biostatistician. Biotechnology http://www.medwellcapital.com/display-press-release.php?id=31 http://www.medwellcapital.com/display-press-release.php?id=31 July 3, 2003 - BioMS Medical Corp (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced that the University of Alberta has received additional patents in Russia, Belarus, Ukraine and the European Union regarding the Company's synthetic peptide therapeutic, MBP8298, for the treatment of MS. BioMS Medical, through a subsidiary, licenses these patents on an exclusive worldwide basis from the University of Alberta. Biotechnology http://www.medwellcapital.com/display-press-release.php?id=30 http://www.medwellcapital.com/display-press-release.php?id=30 May 30, 2003 - BioMS Medical Corp (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced financial results for the first quarter ended March 31, 2003. Biotechnology http://www.medwellcapital.com/display-press-release.php?id=2 http://www.medwellcapital.com/display-press-release.php?id=2 Company plans pivotal trial in Multiple Sclerosis Biotechnology http://www.medwellcapital.com/display-press-release.php?id=28 http://www.medwellcapital.com/display-press-release.php?id=28 May 20, 2003 - BioMS Medical Corp (TSX:MS), a leading developer in the treatment of multiple sclerosis (MS), today announced fourth quarter and year-end results for the year ended December 31, 2002. Biotechnology http://www.medwellcapital.com/display-press-release.php?id=27 http://www.medwellcapital.com/display-press-release.php?id=27 March 6, 2003 - BioMS Medical Corp (TSX:MS), a leading developer in the treatment of multiple sclerosis, is pleased to announce that the University of Alberta has received a patent in Australia regarding the Company's synthetic peptide therapeutic, MBP8298, for the treatment of multiple sclerosis (MS). BioMS Medical, through a subsidiary, licenses the MBP8298 patents on an exclusive worldwide basis from the University. Biotechnology http://www.medwellcapital.com/display-press-release.php?id=26 http://www.medwellcapital.com/display-press-release.php?id=26 Phase I Trial Planned for HYC750 Biotechnology http://www.medwellcapital.com/display-press-release.php?id=25 http://www.medwellcapital.com/display-press-release.php?id=25 January 13, 2003 - BioMS Medical Corp (TSX:MS), a leading developer in the treatment of multiple sclerosis, today announced that it has received proceeds of $2,635,008 from the exercise of approximately 658,700 share purchase warrants. Biotechnology http://www.medwellcapital.com/display-press-release.php?id=24 http://www.medwellcapital.com/display-press-release.php?id=24